Drug Profile
Research programme: matrix metalloproteinase inhibitors - Solvotrin Innovations
Alternative Names: SI 1004; SI 1005Latest Information Update: 17 Oct 2019
Price :
$50
*
At a glance
- Originator Solvotrin Innovations
- Class Nitrogen compounds; Tetracyclines
- Mechanism of Action Matrix metalloproteinase 9 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Cardiovascular disorders; Inflammation; Marfan syndrome
Most Recent Events
- 17 Oct 2019 Discontinued - Preclinical for Cancer in Ireland (unspecified route)
- 17 Oct 2019 Discontinued - Preclinical for Cardiovascular disorders in Ireland (unspecified route)
- 17 Oct 2019 Discontinued - Preclinical for Inflammation in Ireland (unspecified route)